Peptide Therapeutics Market : TOC


Back to Report

1. Research Methodology

2. Assumptions & Acronyms Used

3. Executive Summary

4. Global Peptide Therapeutics Market – Scenario Forecast

5. Global Peptide Therapeutics Market Dynamics

5.1.1. Drivers 

5.1.2. Restraints

5.1.3. Opportunity

5.2. Global Peptide Therapeutics Market Trends

5.3. Global Peptide Therapeutics Market – Drug Pipelines & Key Regulations

6. Global Peptide Therapeutics Market Analysis and Forecast By Application Type

6.1. Introduction

6.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Application Type

6.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Application Type

6.2. Global Peptide Therapeutics Market Analysis By Application Type 

6.2.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Cancer Application Type 

6.2.1.1. Zoladex (Goserelin)

6.2.1.2. Velcade (Bortezomib)

6.2.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

6.2.1.4. Others

6.2.1.5. Global Peptide Therapeutics Market Absolute $ Opportunity, by Cardiovascular Application Type 

6.2.1.6. Angiomax (Bivalirudin)

6.2.1.8. Integrilin (Eptifibatide)

6.2.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Central Nervous System Application Type

6.2.2.1. Application Type 

6.2.2.2. Copaxone (Glatiramer)

6.2.3. Global Peptide Therapeutics Market Absolute $ Opportunity, by Metabolic Disorders Application Type

6.2.3.1. Victoza (Liraglutide)

6.2.3.2. Byetta (Exenatide)

6.2.3.3. Others

6.2.4. Global Peptide Therapeutics Market Absolute $ Opportunity, by Infection Application Type

6.2.4.1. Incivek (Telaprevir)

6.2.4.2. Victrelis (Boceprevir)

6.2.5. Global Peptide Therapeutics Market Absolute $ Opportunity, by Hematological Disorders Application Type

6.2.5.1. Firazyr (Icatibant)

6.2.5.2. Kalbitor (Ecallantide)

6.2.6. Global Peptide Therapeutics Market Absolute $ Opportunity, by Gastrointestinal Disorders Application Type

6.2.6.1. Gattex (Teduglutide)

6.2.6.2. Linzess (Linaclotide)

6.2.7. Global Peptide Therapeutics Market Absolute $ Opportunity, by Dermatology Application Type

6.2.8. Global Peptide Therapeutics Market Absolute $ Opportunity, by Respiratory Disorders Application Type

6.2.9. Global Peptide Therapeutics Market Absolute $ Opportunity, by Endocrinology Application Type

6.2.10. Global Peptide Therapeutics Market Absolute $ Opportunity, by Other Application Type

6.3. Global Peptide Therapeutics Market Attractiveness Analysis By Application Type

7. Global Peptide Therapeutics Market Analysis and Forecast By Route Of Administration

7.1. Introduction

7.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Route Of Administration

7.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Route Of Administration

7.2. Global Peptide Therapeutics Market Analysis By Route Of Administration 

7.2.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Parenteral Route Of Administration 

7.2.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Mucosal Route Of Administration 

7.2.3. Global Peptide Therapeutics Market Absolute $ Opportunity, by Oral Route Of Administration

7.2.4. Global Peptide Therapeutics Market Absolute $ Opportunity, by Transdermal Route Of Administration

7.3. Global Peptide Therapeutics Market Attractiveness Analysis By Route Of Administration

8. Global Peptide Therapeutics Market Analysis and Forecast By Drug Type

8.1. Introduction

8.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Drug Type

8.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Drug Type

8.2. Global Peptide Therapeutics Market Analysis By Drug Type 

8.2.1.1. Global Peptide Therapeutics Market Absolute $ Opportunity, by Branded Drug Type 

8.2.1.2. Global Peptide Therapeutics Market Absolute $ Opportunity, by Generic Drug Type 

8.3. Global Peptide Therapeutics Market Attractiveness Analysis By Drug Type

9. Global Peptide Therapeutics Market Analysis and Forecast By Region

9.1. Introduction 

9.1.1. Global Peptide Therapeutics Market Value Share and BPS Analysis By Region

9.1.2. Global Peptide Therapeutics Market Y-o-Y Growth Rate By Region

9.1.3. Global Peptide Therapeutics Market Value Share (%) By Region, 2015 & 2025

9.2. Global Peptide Therapeutics Market Attractiveness Analysis By Region

9.3. North America Peptide Therapeutics Market Analysis & Forecast

9.3.1. North America Peptide Therapeutics Market Value Forecast By Country

9.3.1.1. Canada

9.3.1.2. U.S.

9.3.2. North America Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.3.3. North America Peptide Therapeutics Market Value Forecast By Application Type

9.3.3.1. Cancer

9.3.3.1.1. Zoladex (Goserelin)

9.3.3.1.2. Velcade (Bortezomib)

9.3.3.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.3.3.1.4. Others

9.3.3.2. Cardiovascular

9.3.3.2.1. Angiomax (Bivalirudin)

9.3.3.2.2. Integrilin (Eptifibatide)

9.3.3.3. Central Nervous System

9.3.3.3.1. Copaxone (Glatiramer)

9.3.3.4. Metabolic Disorders

9.3.3.4.1. Victoza (Liraglutide)

9.3.3.4.2. Byetta (Exenatide)

9.3.3.4.3. Others

9.3.3.5. Infection

9.3.3.5.1. Incivek (Telaprevir)

9.3.3.5.2. Victrelis (Boceprevir)

9.3.3.6. Hematological Disorders

9.3.3.6.1. Firazyr (Icatibant)

9.3.3.6.2. Kalbitor (Ecallantide)

9.3.3.7. Gastrointestinal Disorders

9.3.3.7.1. Gattex (Teduglutide)

9.3.3.7.2. Linzess (Linaclotide)

9.3.3.8. Dermatology

9.3.3.9. Respiratory Disorders

9.3.3.10. Endocrinology

9.3.3.11. Other Applications 

9.3.4. North America Peptide Therapeutics Market Value Forecast By Route Of Administration

9.3.4.1. Parenteral Route

9.3.4.2. Mucosal Route

9.3.4.3. Oral Route

9.3.4.4. Transdermal Route

9.3.5. North America Peptide Therapeutics Market Value Forecast By Drug Type

9.3.5.1. Branded

9.3.5.2. Generic

9.3.6. North America Peptide Therapeutics Market Impact Analysis

9.4. Latin America Peptide Therapeutics Market Analysis & Forecast

9.4.1. Latin America Peptide Therapeutics Market Trends

9.4.2. Latin America Peptide Therapeutics Market Value Forecast By Country

9.4.2.1. Brazil

9.4.2.2. Mexico

9.4.2.3. Rest Of Latin America

9.4.3. Latin America Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.4.4. Latin America Peptide Therapeutics Market Value Forecast By Application Type

9.4.4.1. Cancer

9.4.4.1.1. Zoladex (Goserelin)

9.4.4.1.2. Velcade (Bortezomib)

9.4.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.4.4.1.4. Others

9.4.4.2. Cardiovascular

9.4.4.2.1. Angiomax (Bivalirudin)

9.4.4.2.2. Integrilin (Eptifibatide)

9.4.4.3. Central Nervous System

9.4.4.3.1. Copaxone (Glatiramer)

9.4.4.4. Metabolic Disorders

9.4.4.4.1. Victoza (Liraglutide)

9.4.4.4.2. Byetta (Exenatide)

9.4.4.4.3. Others

9.4.4.5. Infection

9.4.4.5.1. Incivek (Telaprevir)

9.4.4.5.2. Victrelis (Boceprevir)

9.4.4.6. Hematological Disorders

9.4.4.6.1. Firazyr (Icatibant)

9.4.4.6.2. Kalbitor (Ecallantide)

9.4.4.7. Gastrointestinal Disorders

9.4.4.7.1. Gattex (Teduglutide)

9.4.4.7.2. Linzess (Linaclotide)

9.4.4.8. Dermatology

9.4.4.9. Respiratory Disorders

9.4.4.10. Endocrinology

9.4.4.11. Other Applications 

9.4.5. Latin America Peptide Therapeutics Market Value Forecast By Route Of Administration

9.4.5.1. Parenteral Route

9.4.5.2. Mucosal Route

9.4.5.3. Oral Route

9.4.5.4. Transdermal Route

9.4.6. Latin America Peptide Therapeutics Market Value Forecast By Drug Type

9.4.6.1. Branded

9.4.6.2. Generic

9.4.7. Latin America Peptide Therapeutics Market Impact Analysis

9.5. Western Europe Peptide Therapeutics Market Analysis & Forecast

9.5.1. Western Europe Peptide Therapeutics Market Trends

9.5.2. Western Europe Peptide Therapeutics Market Value Forecast By Country

9.5.2.1. Germany

9.5.2.2. UK

9.5.2.3. France

9.5.2.4. Italy

9.5.2.5. Spain

9.5.2.6. Nordic countries

9.5.2.7. BENELUX

9.5.2.8. Rest Of Western Europe

9.5.3. Western Europe Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.5.4. Western Europe Peptide Therapeutics Market Value Forecast By Application Type

9.5.4.1. Cancer

9.5.4.1.1. Zoladex (Goserelin)

9.5.4.1.2. Velcade (Bortezomib)

9.5.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.5.4.1.4. Others

9.5.4.2. Cardiovascular

9.5.4.2.1. Angiomax (Bivalirudin)

9.5.4.2.2. Integrilin (Eptifibatide)

9.5.4.3. Central Nervous System

9.5.4.3.1. Copaxone (Glatiramer)

9.5.4.4. Metabolic Disorders

9.5.4.4.1. Victoza (Liraglutide)

9.5.4.4.2. Byetta (Exenatide)

9.5.4.4.3. Others

9.5.4.5. Infection

9.5.4.5.1. Incivek (Telaprevir)

9.5.4.5.2. Victrelis (Boceprevir)

9.5.4.6. Hematological Disorders

9.5.4.6.1. Firazyr (Icatibant)

9.5.4.6.2. Kalbitor (Ecallantide)

9.5.4.7. Gastrointestinal Disorders

9.5.4.7.1. Gattex (Teduglutide)

9.5.4.7.2. Linzess (Linaclotide)

9.5.4.8. Dermatology

9.5.4.9. Respiratory Disorders

9.5.4.10. Endocrinology

9.5.4.11. Other Applications 

9.5.5. Western Europe Peptide Therapeutics Market Value Forecast By Route Of Administration

9.5.5.1. Parenteral Route

9.5.5.2. Mucosal Route

9.5.5.3. Oral Route

9.5.5.4. Transdermal Route

9.5.6. Western Europe Peptide Therapeutics Market Value Forecast By Drug Type

9.5.6.1. Branded

9.5.6.2. Generic

9.5.7. Western Europe Peptide Therapeutics Market Impact Analysis

9.6. Eastern Europe Peptide Therapeutics Market Analysis & Forecast

9.6.1. Eastern Europe Peptide Therapeutics Market Trends

9.6.2. Eastern Europe Peptide Therapeutics Market Value Forecast By Country

9.6.2.1. Russia

9.6.2.2. Poland

9.6.2.3. Rest Of Eastern Europe

9.6.3. Eastern Europe Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.6.4. Eastern Europe Peptide Therapeutics Market Value Forecast By Application Type

9.6.4.1. Cancer

9.6.4.1.1. Zoladex (Goserelin)

9.6.4.1.2. Velcade (Bortezomib)

9.6.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.6.4.1.4. Others

9.6.4.2. Cardiovascular

9.6.4.2.1. Angiomax (Bivalirudin)

9.6.4.2.2. Integrilin (Eptifibatide)

9.6.4.3. Central Nervous System

9.6.4.3.1. Copaxone (Glatiramer)

9.6.4.4. Metabolic Disorders

9.6.4.4.1. Victoza (Liraglutide)

9.6.4.4.2. Byetta (Exenatide)

9.6.4.4.3. Others

9.6.4.5. Infection

9.6.4.5.1. Incivek (Telaprevir)

9.6.4.5.2. Victrelis (Boceprevir)

9.6.4.6. Hematological Disorders

9.6.4.6.1. Firazyr (Icatibant)

9.6.4.6.2. Kalbitor (Ecallantide)

9.6.4.7. Gastrointestinal Disorders

9.6.4.7.1. Gattex (Teduglutide)

9.6.4.7.2. Linzess (Linaclotide)

9.6.4.8. Dermatology

9.6.4.9. Respiratory Disorders

9.6.4.10. Endocrinology

9.6.4.11. Other Applications 

9.6.5. Eastern Europe Peptide Therapeutics Market Value Forecast By Route Of Administration

9.6.5.1. Parenteral Route

9.6.5.2. Mucosal Route

9.6.5.3. Oral Route

9.6.5.4. Transdermal Route

9.6.6. Eastern Europe Peptide Therapeutics Market Value Forecast By Drug Type

9.6.6.1. Branded

9.6.6.2. Generic

9.6.7. Eastern Europe Peptide Therapeutics Market Impact Analysis

9.7. APEJ Peptide Therapeutics Market Analysis & Forecast

9.7.1. APEJ Peptide Therapeutics Market Trends

9.7.2. APEJ Peptide Therapeutics Market Value Forecast By Country

9.7.2.1. China

9.7.2.2. India

9.7.2.3. Australia & New Zealand

9.7.2.4. Rest Of APEJ

9.7.3. APEJ Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.7.4. APEJ Peptide Therapeutics Market Value Forecast By Application Type

9.7.4.1. Cancer

9.7.4.1.1. Zoladex (Goserelin)

9.7.4.1.2. Velcade (Bortezomib)

9.7.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.7.4.1.4. Others

9.7.4.2. Cardiovascular

9.7.4.2.1. Angiomax (Bivalirudin)

9.7.4.2.2. Integrilin (Eptifibatide)

9.7.4.3. Central Nervous System

9.7.4.3.1. Copaxone (Glatiramer)

9.7.4.4. Metabolic Disorders

9.7.4.4.1. Victoza (Liraglutide)

9.7.4.4.2. Byetta (Exenatide)

9.7.4.4.3. Others

9.7.4.5. Infection

9.7.4.5.1. Incivek (Telaprevir)

9.7.4.5.2. Victrelis (Boceprevir)

9.7.4.6. Hematological Disorders

9.7.4.6.1. Firazyr (Icatibant)

9.7.4.6.2. Kalbitor (Ecallantide)

9.7.4.7. Gastrointestinal Disorders

9.7.4.7.1. Gattex (Teduglutide)

9.7.4.7.2. Linzess (Linaclotide)

9.7.4.8. Dermatology

9.7.4.9. Respiratory Disorders

9.7.4.10. Endocrinology

9.7.4.11. Other Applications 

9.7.5. APEJ Peptide Therapeutics Market Value Forecast By Route Of Administration

9.7.5.1. Parenteral Route

9.7.5.2. Mucosal Route

9.7.5.3. Oral Route

9.7.5.4. Transdermal Route

9.7.6. APEJ Peptide Therapeutics Market Value Forecast By Drug Type

9.7.6.1. Branded

9.7.6.2. Generic

9.7.7. APEJ Peptide Therapeutics Market Impact Analysis

9.8. Japan Peptide Therapeutics Market Analysis & Forecast

9.8.1. Japan Peptide Therapeutics Market Trends

9.8.2. Japan Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.8.3. Japan Peptide Therapeutics Market Value Forecast By Application Type

9.8.3.1. Cancer

9.8.3.1.1. Zoladex (Goserelin)

9.8.3.1.2. Velcade (Bortezomib)

9.8.3.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.8.3.1.4. Others

9.8.3.2. Cardiovascular

9.8.3.2.1. Angiomax (Bivalirudin)

9.8.3.2.2. Integrilin (Eptifibatide)

9.8.3.3. Central Nervous System

9.8.3.3.1. Copaxone (Glatiramer)

9.8.3.4. Metabolic Disorders

9.8.3.4.1. Victoza (Liraglutide)

9.8.3.4.2. Byetta (Exenatide)

9.8.3.4.3. Others

9.8.3.5. Infection

9.8.3.5.1. Incivek (Telaprevir)

9.8.3.5.2. Victrelis (Boceprevir)

9.8.3.6. Hematological Disorders

9.8.3.6.1. Firazyr (Icatibant)

9.8.3.6.2. Kalbitor (Ecallantide)

9.8.3.7. Gastrointestinal Disorders

9.8.3.7.1. Gattex (Teduglutide)

9.8.3.7.2. Linzess (Linaclotide)

9.8.3.8. Dermatology

9.8.3.9. Respiratory Disorders

9.8.3.10. Endocrinology

9.8.3.11. Other Applications 

9.8.4. Japan Peptide Therapeutics Market Value Forecast By Route Of Administration

9.8.4.1. Parenteral Route

9.8.4.2. Mucosal Route

9.8.4.3. Oral Route

9.8.4.4. Transdermal Route

9.8.5. Japan Peptide Therapeutics Market Value Forecast By Drug Type

9.8.5.1. Branded

9.8.5.2. Generic

9.8.6. Japan Peptide Therapeutics Market Impact Analysis

9.9. MEA Peptide Therapeutics Market Analysis & Forecast

9.9.1. MEA Peptide Therapeutics Market Trends

9.9.2. MEA Peptide Therapeutics Market Value Forecast By Country

9.9.2.1. GCC Countries

9.9.2.2. South Africa

9.9.2.3. Israel

9.9.2.4. Rest Of MEA

9.9.3. MEA Peptide Therapeutics Market Absolute $ Opportunity, 2014–2025

9.9.4. MEA Peptide Therapeutics Market Value Forecast By Application Type

9.9.4.1. Cancer

9.9.4.1.1. Zoladex (Goserelin)

9.9.4.1.2. Velcade (Bortezomib)

9.9.4.1.3. Lupron/ Enantone/ Eligard (leuprorelin)

9.9.4.1.4. Others

9.9.4.2. Cardiovascular

9.9.4.2.1. Angiomax (Bivalirudin)

9.9.4.2.2. Integrilin (Eptifibatide)

9.9.4.3. Central Nervous System

9.9.4.3.1. Copaxone (Glatiramer)

9.9.4.4. Metabolic Disorders

9.9.4.4.1. Victoza (Liraglutide)

9.9.4.4.2. Byetta (Exenatide)

9.9.4.4.3. Others

9.9.4.5. Infection

9.9.4.5.1. Incivek (Telaprevir)

9.9.4.5.2. Victrelis (Boceprevir)

9.9.4.6. Hematological Disorders

9.9.4.6.1. Firazyr (Icatibant)

9.9.4.6.2. Kalbitor (Ecallantide)

9.9.4.7. Gastrointestinal Disorders

9.9.4.7.1. Gattex (Teduglutide)

9.9.4.7.2. Linzess (Linaclotide)

9.9.4.8. Dermatology

9.9.4.9. Respiratory Disorders

9.9.4.10. Endocrinology

9.9.4.11. Other Applications 

9.9.5. MEA Peptide Therapeutics Market Value Forecast By Route Of Administration

9.9.5.1. Parenteral Route

9.9.5.2. Mucosal Route

9.9.5.3. Oral Route

9.9.5.4. Transdermal Route

9.9.6. MEA Peptide Therapeutics Market Value Forecast By Drug Type

9.9.6.1. Branded

9.9.6.2. Generic

9.9.7. MEA Peptide Therapeutics Market Impact Analysis

10. Company Profiles

10.1. Company Dashboard

10.2. Company Profiles

10.2.1. AstraZeneca plc

10.2.2. Bachem Holding AG

10.2.3. CordenPharma International 

10.2.4. Eli Lilly and Company

10.2.5. Ipsen S.A

10.2.6. Merck & Co., Inc

10.2.7. Novo Nordisk A/S

10.2.8. PolyPeptide Group

10.2.9. Teva Pharmaceutical Industries Ltd

Request Methodology of This Report

Request Methodology

First Time Buyer ?

Check Discount

Request a Sample

Click button below to request a sample of this report

Request Sample

About This Report


  • Rep Id : XPLREP877
  • Publised On : November, 2015
  • No. of Pages : 111
  • Category : Biopharmaceutical
  • Publisher : Future Market Insights